For Some, Oral Insulin’s Allure Persists Despite Hurdles
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The recent release of preliminary Phase III results for Generex Biotechnology Corp.’s buccal spray Oral-lyn put the challenging, but alluring for a few dogged developers, oral insulin development space back in the spotlight momentarily.